Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept by Verazza, Sara et al.
RESEARCH ARTICLE Open Access
Disease status, reasons for discontinuation
and adverse events in 1038 Italian children
with juvenile idiopathic arthritis treated
with etanercept
Sara Verazza1, Sergio Davì2, Alessandro Consolaro1,2, Francesca Bovis2, Antonella Insalaco3, Silvia Magni-Manzoni3,
Rebecca Nicolai3, Denise Pires Marafon3, Fabrizio De Benedetti3, Valeria Gerloni4, Irene Pontikaki4,
Francesca Rovelli4, Rolando Cimaz5, Achille Marino5, Francesco Zulian6, Giorgia Martini6, Serena Pastore7,
Chiara Sandrin7, Fabrizia Corona8, Marta Torcoletti8, Giovanni Conti9, Claudia Fede9, Patrizia Barone10,
Marco Cattalini11, Elisabetta Cortis12, Luciana Breda13, Alma Nunzia Olivieri14, Adele Civino15, Rosanna Podda16,
Donato Rigante17, Francesco La Torre18, Gianfranco D’Angelo19, Mauro Jorini20, Romina Gallizzi21,
Maria Cristina Maggio22, Rita Consolini23, Alessandro De Fanti24, Valentina Muratore25, Maria Giannina Alpigiani2,
Nicolino Ruperto2, Alberto Martini1,2, Angelo Ravelli1,2,26* and on behalf of the Italian Pediatric Rheumatology
Study Group
Abstract
Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic
medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease
status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN).
Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients
given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group
2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All
three groups received a retrospective assessment; patients in group 1 also underwent a cross-sectional assessment.
Results: 1038 patients were enrolled by 23 centers: 422 (40.7%) were in group 1, 462 (44.5%) in group 2, and 154 (14.8%)
in group 3. Median duration of ETN therapy was 2.5 years. At cross-sectional assessment, 41.8% to 48.6% of patients in
group 1 met formal criteria for inactive disease, whereas 52.4% of patients in group 2 and 55.8% of patients in group 3
were judged in clinical remission by their caring physician at last visit. A relatively greater proportion of patients with
systemic arthritis were discontinued or lost to follow-up. Parent evaluations at cross-sectional visit in group 1 showed that
52.4% of patients had normal physical function, very few had impairment in quality of life, 51.2% had no pain, 76% had
no morning stiffness, and 82.7% of parents were satisfied with their child’s illness outcome. Clinically significant adverse
events were reported for 27.8% of patients and ETN was discontinued for side effects in 9.5%. The most common adverse
events were new onset or recurrent uveitis (10.2%), infections (6.6%), injection site reactions (4.4%), and neuropsychiatric
(3.1%), gastrointestinal (2.4%), and hematological disorders (2.1%). Ten patients developed an inflammatory bowel
disease and 2 had a malignancy. One patient died of a fulminant streptococcal sepsis.
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Conclusions: Around half of the patients achieved complete disease quiescence under treatment with ETN. The
medication was overall well tolerated, as only one quarter of patients experienced clinically significant adverse
events and less than 10% had treatment discontinued for toxicity.
Keywords: Juvenile idiopathic arthritis, Etanercept, Pediatric rheumatology, TNF inhibitors, Biologic therapies
Background
Etanercept (ETN), a tumor necrosis factor (TNF) an-
tagonist, has been the first biologic agent registered for
use in children with juvenile idiopathic arthritis (JIA).
Its efficacy and safety have been established in a ran-
domized placebo-controlled withdrawal trial in patients
with a polyarticular disease course who were refractory
or intolerant to methotrexate (MTX) [1]. Long-term
extension studies of the original trial cohort and
national registries have subsequently confirmed the
sustained clinical benefit and acceptable tolerability of
the drug [2–5]. The evidence for the effectiveness of
ETN in JIA has been expanded by the observation that
its administration is associated with improvement of
functional ability and health-related quality of life [6–8],
recovery of growth velocity and bone status [9, 10], and
inhibition of progression of radiographic joint damage
[11]. Recent studies have shown that around half of
children with JIA who are treated with ETN in clinical
practice are able to attain complete disease quiescence
[12–14]. However, there is a need of more data from
large series of patients treated in real-life clinical settings
to fully characterize the efficacy and safety profile of this
medication.
In June 2013, the Italian Pediatric Rheumatology Study
Group undertook a national multicenter survey aimed to
investigate the disease status, reasons for discontinuation
and adverse events in Italian patients with JIA who were
receiving or had received ETN. The findings of this
study, named Etanercept in Italian Children with Arthritis
(EtICA) study, are described in the present article.
Methods
Study design and patient enrolment
All centers that are part of the Italian Pediatric Rheuma-
tology Study Group were invited to participate in this
multicenter, observational study. To minimize a selec-
tion bias, investigators at each center were first asked to
make a census of all patients with JIA by the Inter-
national League of Associations for Rheumatology
(ILAR) criteria [15] who were given ETN at the center
after January 2000 and had received the medication for
at least 6 months. Based on the status of ETN therapy at
the time of the census, patients were classified in three
groups: group 1 = patients still taking ETN; group 2
patients discontinued from ETN for any reasons; group
3 patients lost to follow-up while receiving ETN. Next,
each investigator was asked to make a retrospective
assessment for all patients in groups 1, 2 and 3, and a
cross-sectional assessment at first visit after the census
for all patients in group 1. Study data were collected in
ad hoc case reports forms. Once completed, all forms
were sent to the coordinating center (the Gaslini Institute,
Genoa, Italy). Ethics committee approval of the study
protocol was obtained in all participating centers.
Retrospective assessment
The following information was collected through the
review of patients charts: sex, age at disease onset, ILAR
category, disease duration at first visit at study center
and at start of ETN, medications administered before
ETN start and during ETN therapy, ETN-related side
effects, duration of ETN therapy at treatment discon-
tinuation (for patients in group 2) or at last follow-up
visit (for patients in group 3), reasons for ETN discon-
tinuation (for patients in group 2), and disease activity
state (remission or active disease) at last follow-up visit
(for patients in group 3).
Cross-sectional assessment
The following clinical evaluations were performed at
cross-sectional visit in patients still taking ETN (group 1).
The caring physician made a standardized joint exam-
ination and recorded the count of joints with swelling,
pain/tenderness, restricted motion, and active arthritis [16];
in addition, he or she also rated the overall disease
activity on a 21-numbered circle visual analog scale
(VAS; where 0 = no activity and 10 = maximum activity)
[17]. The same physician also assessed the amount of
articular and extra-articular damage through the Juvenile
Arthritis Damage Index (JADI) [18]. Briefly, the JADI-
Articular (JADI-A) assesses 36 joints or joint groups for
the presence of damage, and the damage observed in each
joint is scored on a 3-point scale (0 = no damage, 1 = par-
tial damage, and 2 = severe damage, ankylosis, or pros-
thesis). The maximum total score is 72. The JADI-
Extraarticular (JADI-E) includes 13 items in 5 different
organs/systems. Each item is scored as 0 if damage is
absent or as 1 if damage is present. Due to the relevant
impact of ocular damage on the child’s health, in each
eye a score of 2 is given in case the patient has had ocular
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surgery, and a score of 3 is given in case the patient has
developed legal blindness. The maximum total score is 17.
Prior to the physician visit, a parent (or guardian)
completed the parent version of the Juvenile Arthritis
Multidimensional Questionnaire (JAMAR) [19]. This
questionnaire incorporates all main parent-centered out-
come measures, including physical function, health-
related quality of life (HRQL), overall well-being, pain,
level of disease activity, self- or proxy-reported joint
count, morning stiffness, assessment of disease status
and course, side effects of medications, therapeutic com-
pliance, difficulties at school, and satisfaction with illness
outcome. We previously found that the mean (SD)
HRQL score in 801 healthy children was 2.6 (2.4) and
that the mean (SD) score of the physical health and
psychosocial health subscales was 0.8 (1.2) and 1.8 (1.7),
respectively (Bertamino M et al. Unpublished observation).
Laboratory investigations included the erythrocyte
sedimentation rate (ESR) and the C-reactive protein
(CRP), but were performed only if deemed necessary by
the caring physician for clinical purposes.
Informed consent to participate in the study was pro-
vided by both the parent/guardian and the patient
(when applicable) for all patients who underwent the
cross-sectional assessment.
Definitions of disease activity states
In patients still taking ETN (group 1), the state of disease
activity at cross-sectional visit was assessed through the
following criteria: 1) criteria for inactive disease (ID) in
JIA [20]; 2) preliminary definition of minimal disease
activity in JIA [21]; 3) criteria for inactive disease and
low disease activity (LDA), moderate disease activity
(MDA), and high disease activity (HDA) in JIA based
on the Juvenile Arthritis Disease Activity Score
(JADAS) and the clinical JADAS (cJADAS) [22–24]. To
harmonize the terminology of disease activity states
with that used in the adult rheumatology community,
in this study, the term minimal disease activity has been
replaced with LDA, which has an identical meaning.
For patients in groups 2 and 3, the disease activity state
at treatment discontinuation or last follow-up visit,
respectively, was defined by the caring physician based
on the data recorded in the clinical chart.
Recording of adverse events
ETN-related adverse events were recorded for all patients
in groups 1, 2 and 3. Study investigators were instructed
to report all adverse events that they considered clinically
significant, without pre-specified definitions of charac-
teristics and severity. Adverse events that led to treat-
ment discontinuation were registered for patients who
had ETN discontinued for side effects.
Statistics
Descriptive statistics are reported as median and inter-
quartile range (IQR) for continuous variables and as abso-
lute frequency and percentage for categorical variables.
Comparisons of disease characteristics between patient
groups were performed by means of Mann-Whitney U
test in case of quantitative data and by means of the chi-
square test, or the Fisher’s Exact test, as appropriate, in
case of categorical data. All statistical tests were two-
sided; a P value of less than 0.05 was considered as statisti-
cally significant. The statistical package used were SAS 9.3
(Institute Inc., Cary, NC, USA) and Statistica (version 8.0,
StatSoft Corp., Tulsa, OK).
Results
All 26 invited pediatric rheumatology centers agreed to
participate in the study and included in the census a
total of 1231 patients. However, 3 centers, which had
listed 109 patients, did not provide any evaluations and
were then excluded. Of the remaining 1122 patients,
1068 (95.2%) underwent the study assessments. Thirty of
them were enrolled by more than one center and were,
thus, counted only once (by retaining the most recent
assessment), leading to a final number of assessed pa-
tients of 1038. Of them, 422 (40.7%) were still receiving
ETN (group 1), 462 (44.5%) had been discontinued
from ETN (group 2), and 154 (14.8%) had been lost to
follow-up while receiving ETN (group 3). For the
purpose of the analyses, patients in group 1 were placed
in a “cross-sectional group” and patients in groups 2
and 3, who received only retrospective assessments,
were combined in a single “retrospective group”.
The characteristics of the study patients at the start of
ETN therapy are presented in Table 1. Overall, the study
cohort was characterized by marked female prevalence,
young age at onset, and high frequency of ANA posi-
tivity. The median disease duration (3.5 years) was
quite long, but the average duration of follow-up at the
study center was 2.1 years. Around two third of patients
had extended oligoarthritis or rheumatoid factor-negative
polyarthritis. Patients with persistent oligoarthritis out-
numbered those with psoriatic arthritis, enthesitis-related
arthritis, or undifferentiated arthritis. There were more
patients with systemic arthritis in the retrospective group
than in the cross-sectional group. Patients in the cross-
sectional group had a younger age at disease onset and
were more frequently ANA positive than those in the
retrospective group. Before the start of ETN, approxi-
mately 90% of the patients had received MTX, 50%
systemic corticosteroids, and 55% intra-articular corti-
costeroids. 53 patients were given biologic medica-
tions other than ETN before treatment start, which
included adalimumab (n = 20), infliximab (n = 19),
anakinra (n = 15), abatacept (n = 3), and tocilizumab
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(n = 1). During ETN therapy, more than 70% of the
patients were given concomitant MTX therapy and
around 25% corticosteroids, either systemic or intra-
articular. The median (IQR) duration of ETN therapy
in the cross-sectional and retrospective group was 2.5
(1–4.2) years and 2.6 (1.3–4.4) years, respectively.
79.5% of patients were treated for at least 1 year, 58.5% for
at least 2 years, and 19.1% for at least 5 years.
Table 2 shows the disease activity states and concomi-
tant therapies at cross-sectional visit in patients still
receiving ETN (cross-sectional group). The percentage
of patients who met the Wallace criteria for ID [20] and
the Magni-Manzoni criteria for LDA (or minimal disease
activity) [21] was 41.8 and 63.6%, respectively. Notably,
the exclusion of the criterion that requires the normality
of acute phase reactants from Wallace criteria led to in-
crease the proportion of patients with ID to 51%. The
percentage of patients who met the JADAS10 criteria for
ID, LDA, MDA and HDA [22, 23] was 46.4, 64.0, 24.4,
and 11.6%, respectively. The figures obtained for the
cJADAS10 [24] were similar. 68.5% of patients had no
active joints and 56.6% had a physician global assess-
ment indicating no disease activity. More than 80% of
patients had normal ESR or CRP. 77.3 and 86.9% of
patients had no evidence of articular or extra-articular
damage, respectively. As compared to treatment baseline,
Table 1 Baseline characteristics of children with juvenile idiopathic arthritis treated with etanercepta
All patients
(n = 1038)
Cross-sectional groupb
(n = 422)
Retrospective groupc
(n = 616)
P
Female 781 (75.2) 335 (79.4) 446 (72.4) 0.01
ILAR category
Systemic arthritis 106 (10.2) 21 (5) 85 (13.8) <0.0001
Persistent oligoarthritis 139 (13.4) 60 (14.2) 79 (12.8) 0.52
Extended oligoarthritis 325 (31.3) 147 (34.8) 178 (28.9) 0.04
RF-negative polyarthritis 329 (31.7) 138 (32.7) 191 (31) 0.56
RF-positive polyarthritis 50 (4.8) 16 (3.8) 34 (5.5) 0.20
Enthesitis-related arthritis 48 (4.6) 21 (5) 27 (4.4) 0.65
Psoriatic arthritis 34 (3.3) 16 (3.8) 18 (2.9) 0.44
Undifferentiated arthritis 7 (0.7) 3 (0.7) 4 (0.6) 1.0
Patients with positive ANA 586/1028 (57) 278 (66.5) 308 (50.5) <0.0001
Median (IQR) age at disease onset, years 4.1 (2–8.3) 3.5 (1.8–7.3) 4.7 (2.1–9.1) 0.001
Median (IQR) age, years 10.1 (6.2–13.9) 9.6 (5.8–13.6) 10.4 (6.9–14.2) 0.04
Median (IQR) disease duration, years 3.5 (1.3–7.5) 3.6 (1.4–7.8) 3.3 (1.3–7.3) 0.16
Patients aged < 4 years 122 (11.8) 54 (12.8) 68 (11) 0.39
Median (IQR) follow-up durationd, years 2.1 (0.6–5.5) 2.4 (0.7–6.3) 2.1 (0.5–5.1) 0.04
Treatments before ETN start
NSAIDs 603 (58.1) 269 (63.7) 334 (54.2) 0.002
Systemic corticosteroids 527 (50.8) 198 (46.9) 329 (53.4) 0.04
Intra-articular corticosteroids 579 (55.8) 263 (62.3) 316 (51.3) 0.0004
Methotrexate 930 (89.6) 387 (91.7) 543 (88.1) 0.07
Other synthetic DMARDs 187 (18) 48 (11.4) 139 (22.6) <0.0001
Other biologic agents 53 (5.1) 18 (4.3) 35 (5.7) 0.31
Concomitant therapies during ETN administration
Systemic corticosteroids 267 (25.7) 93 (22) 174 (28.2) 0.02
Intra-articular corticosteroids 257 (24.8) 98 (23.2) 159 (25.8) 0.34
Methotrexate 749 (72.2) 311 (73.7) 438 (71.1) 0.36
Other synthetic DMARDs 73 (7) 17 (4) 56 (9.1) 0.002
ILAR International League of Associations for Rheumatology, ANA antinuclear antibodies, ETN etanercept, IQR interquartile range, NSAIDs nonsteroidal
anti-inflammatory drugs, DMARDs disease-modifying antirheumatic drugs
aData are number (percentage) unless otherwise indicated
bIncludes patients still receiving ETN
cIncludes patients discontinued from ETN or lost to follow-up
dDuration of follow-up at study center
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the percentage of patients who were still receiving con-
comitant MTX therapy at cross-sectional visit was de-
creased from 73.7 to 47.4% and the percentage of patients
who were taking systemic corticosteroids was diminished
from 22 to 4.7%. Only 2.6% of patients underwent intra-
articular corticosteroid administration at cross-sectional
visit. Of the 21 patients with systemic arthritis who were
still receiving ETN, 15.8 and 9.5% had ID by Wallace and
JADAS criteria, respectively, and 23.8 and 28.6% had LDA
by Magni-Manzoni and JADAS criteria, respectively.
Parent-reported outcomes obtained at cross-sectional
visit through the completion of the JAMAR are summa-
rized in Table 3. Around half of the patients had normal
physical function and only 22.1% had impairment in
HRQL, as demonstrated by a HRQL score 1SD above
the mean of healthy children. HRQL impairment was
more common in the physical than in the psychosocial
domains (48.7% vs. 19.7%). 46% of patients had a parent
global assessment indicating good well-being and around
half had no pain. The median (IQR) pain VAS score was
0 and, among patients who had a pain score > 0, 68.8,
23.6 and 7.6% had a score ≤ 1, 1–5 or > 5, respectively.
Three quarter of patients had no morning stiffness and
around two third were judged by their parents as being
in the state of remission. 82.7% of parents were satisfied
with the current state of their child’s illness.
Table 2 Therapeutic data and disease activity states at cross-sectional visit in patients still receiving etanercept (n = 422)a
No assessed No (%) positive
Concomitant therapies
Systemic corticosteroids 422 20 (4.7)
Intra-articular corticosteroids 422 11 (2.6)
Methotrexate 422 200 (47.4)
Salazopyrin 422 3 (0.7)
Azathioprine 422 1 (0.2)
Disease activity states – Formal definitions
Wallace criteria for inactive disease 392 164 (41.8)
Wallace criteria for inactive disease without
acute phase reactants
420 214 (51)
Magni-Manzoni criteria for low disease activity 420 267 (63.6)
Disease activity states – JADAS10
Inactive disease 422 196 (46.4)
Low disease activityb 422 270 (64)
Moderate disease activity 422 103 (24.4)
High disease activity 422 49 (11.6)
Disease activity states – cJADAS10
Inactive disease 422 205 (48.6)
Low disease activityb 422 246 (58.3)
Moderate disease activity 422 117 (27.7)
High disease activity 422 59 (14)
Patients with no active joints 422 289 (68.5)
Patients with no swollen joints 422 313 (74.2)
Patients with no tender joints 422 299 (70.9)
Patients with no restricted joints 422 253 (60)
Patients with physician’s VAS = 0 422 239 (56.6)
Patients with ESR < 20 mm/h 398 321 (80.7)
Patients with normal CRP 402 341 (84.8)
Patients with JADI Articular = 0 419 324 (77.3)
Patients with JADI Extraarticular = 0 419 364 (86.9)
IQR interquartile range, JADAS Juvenile Arthritis Disease Activity Score, VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADI
Juvenile Arthritis Damage Index
aData are number (percentage) unless otherwise indicated
bIncludes patients with inactive disease
Verazza et al. Pediatric Rheumatology  (2016) 14:68 Page 5 of 11
The achievement of disease remission was the leading
cause of treatment discontinuation (52.4% of patients),
followed by treatment inefficacy (29%), adverse events
(21%), and parent decision/lack of adherence (2.6%).
More than half of the patients lost to follow-up (55.8%)
were in clinical remission at the time of last visit. Of the
70 patients with systemic arthritis who were discontinued
from ETN, 19 (27.1%) and 45 (64.3%) had treatment with-
drawn for disease remission and inefficacy, respectively.
Among the 108 patients (10.4%) who had not received
MTX before ETN start, 35 were in the cross-sectional
group and 73 were in the retrospective group. In the
former group, the frequency of ID by Wallace and
JADAS criteria was 25 and 28.6%, respectively, and the
frequency of LDA by Magni-Manzoni and JADAS
criteria was 44.1 and 51.4%, respectively. 71% per cent of
the patients in the latter group had disease remission at
treatment discontinuation or last follow-up visit.
One or more adverse events were reported for 27.8%
of the patients. The most common were new onset or
recurrence of uveitis (10.2%), infections (6.6%), injection
site reactions (4.4%), neuropsychiatric disorders (3.1%),
gastrointestinal disorders (2.4%), hematological disorders
(2.1%), muco-cutaneous disorders (1.9%), and pain at the
injection site (1.8%). Infectious complications were most
frequently mild as in only 13 of 68 cases they led to
treatment withdrawal. The side effects that led to treat-
ment discontinuation in the 99 patients who were with-
drawn from ETN for toxicity are presented in Table 4.
Those that led to treatment discontinuation in more
than 5% of patients were recurrence or new onset of
uveitis, neuropsychiatric disorders, gastrointestinal disor-
ders, infections, muco-cutaneous disorders, and
hematologic disorders. Among these patients, the most
common neuropsychiatric manifestations were behav-
ioral disorders and headache, whereas urticaria and
leukopenia were the most frequently reported mucocu-
taneous and hematologic disorders, respectively. Seven
patients had injection site reaction or pain at injection
site. Only 1 patient developed tuberculosis.
Table 3 Parent-reported outcomes at cross-sectional visit in patients still receiving ETN
No assessed
Median (IQR) physical function scorea 420 0 (0; 3)
No (%) of patients with physical function score = 0 420 220 (52.4)
Median (IQR) HRQL scoreb 417 2 (0; 5)
No (%) of patients with HRQL score > 1 DS above the mean of healthy children 417 92 (22.1)
Median (IQR) HRQL PhH scorec 417 1 (0; 3)
No (%) of patients with HRQL PhH score > 1 DS above the mean of healthy children 417 203 (48.7)
Median (IQR) HRQL PsH scorec 417 1 (0; 3)
No (%) of patients with HRQL PsH > 1 DS above the mean of healthy children 417 82 (19.7)
Median (IQR) VAS well-beingd 420 0.5 (0; 3)
No (%) of patients with VAS well-being = 0 420 193 (46)
Median (IQR) VAS paind 420 0 (0; 2,5)
No (%) of patients with VAS pain = 0 420 215 (51.2)
No (%) of patients with VAS pain ≤1 420 289 (68.8)
No (%) of patients with VAS pain from 1.5 to 5 420 99 (23.6)
No (%) of patients with VAS pain >5 420 32 (7.6)
Median (IQR) VAS disease activityd 420 0 (0; 2)
No (%) of patients with VAS disease activity = 0 420 224 (53.3)
No (%) of patients with no morning stiffness 420 319 (76)
Disease activity state
No (%) of patients with remission 421 286 (67.9)
No (%) of patients with continued activity 421 86 (20.4)
No (%) of patients with disease flare 421 49 (11.6)
No (%) of parents satisfied with their child’s illness outcome 399 330 (82.7)
IQR interquartile range, HRQL health-related quality of life, PhH Physical Health, PsH Psychosocial Health, VAS visual analog scale
aScore ranges from 0 (no disability) to 30 (maximum disability)
bScore ranges from 0 to 30, higher scores indicate worse HRQL
cScore ranges 0–15, higher scores indicate worse HRQL
dAll VAS range from 0 (best) to 10 (worst)
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The prevalence of uveitis was 52/314 (16.6%) among
patients who were started with ETN before December
2006 and 54/724 (7.5%) among patients treated after
January 2007. Furthermore, the 38 patients who had
ETN discontinued due to the occurrence of uveitis had a
median duration of ETN therapy longer than that of the
entire patient cohort (3.4 and 2.5 years, respectively). Of
the 10 patients who developed an inflammatory bowel
disease, 4 had rheumatoid-factor negative polyarthritis, 2
oligoarthritis, 2 enthesitis-related arthritis, 1 rheumatoid-
factor positive polyarthritis, and 1 psoriatic arthritis. Two
patients had a malignancy while receiving ETN. The first
was a 16-year old boy with persistent oligoarthritis who
developed a thyroid carcinoma 1 year after the start of
ETN. The disease duration at start of ETN was 3.7 years
and the medication regimen before ETN initiation had
included MTX and intra-articular corticosteroids. The
second patient had a bladder carcinoma after 9.4 years
of ETN administration. He was a boy with systemic
arthritis who had a disease duration of 5.8 years at ETN
start and had previously received MTX and systemic
corticosteroids and intra-articular corticosteroids. The
sole patient in the study cohort who died was a 5-year
old child with systemic arthritis who was taking ETN
and MTX and had a fulminant streptococcal sepsis,
which developed as a complication of bilateral bron-
chopneumonia and pleurisy. He had previously received
systemic corticosteroids and anakinra.
Discussion
Our study describes the experience with the use of ETN
in Italian children with JIA. Because all but 3 centers
that are part of the Italian Pediatric Rheumatology Study
Group participated in the study and more than 95% of
patients included in the census underwent the cross-
sectional or retrospective assessments, the results of our
survey are generalizable to all JIA patients who received
ETN in Italy in the study period. To obtain a precise
and reliable documentation of the disease status of chil-
dren on ongoing ETN therapy, we applied a comprehen-
sive set of physician-centered and parent-centered
outcome measures. These data provide a benchmarking
for future outcome comparisons with other cohorts of
JIA patients under therapy with ETN or other biologic
medications.
Table 4 Adverse events that led to treatment discontinuation
in 99 patients
Adverse event N
Recurrent or new-onset uveitis 38
Neuropsychiatric disorders 21
Behavioral disorders 7
Headache 6
Mood disorders/difficulty concentrating 4
Tics/unintentional movements 2
Papilledema 1
Hypoglossal nerve paralysis 1
Gastrointestinal disorders 15
Inflammatory bowel diseases 10
Persistent hypertransaminasemia 1
Abdominal pain 1
Peritonitis anti-DNA positive 1
Acute pancreatitis 1
Nausea or vomiting 1
Infection 13
Recurrent herpes labialis 2
Recurrent upper airway infections 2
Fatal streptococcal sepsis 1
Tuberculosis 1
Varicella complicated by porpora fulminans and fasciitis 1
Osteomyielitis 1
Cellulitis 1
Herpetic neuritis 1
Herpes zoster 1
CMV hepatitis 1
Recurrent bronchitis 1
Mucocutaneous disorders 10
Urticaria 4
Urticaria angioedema 2
Cutaneous vasculitis 2
Itch 1
Anal Condylomatosis 1
Haematological disorders 5
Leukopenia 3
Autoimmune thrombocytopenia 1
Hypocomplementemia 1
Injection site reactions 4
Pain at injection site 3
Malignancy 2
Thyroid carcinoma 1
Bladder carcinoma 1
Others 6
Table 4 Adverse events that led to treatment discontinuation
in 99 patients (Continued)
Persistent cervical lymphadenopathy 2
Autoimmune thyroiditis 1
Menometrorrhagia 1
Abortion 1
Renal lithiasis 1
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We found that 41.8 to 48.6% of patients (depending of
the definition used) who were still receiving ETN at the
time of the census met the criteria for ID, 52.4% of
patients who were discontinued from ETN had the medi-
cation stopped for clinical remission, and 55.8% of
patients who were lost to follow-up were in clinical remis-
sion at last visit. Altogether, these findings concur with
earlier reports that around half of JIA patients treated with
ETN in standard clinical care are able to attain complete
disease quiescence [12–14]. The strong disease-controlling
potential of ETN was strengthened by the observation that
in the cross-sectional sample 58.3 to 64% of patients had
LDA and less than 15% had HDA. In addition, at cross-
sectional visit the proportion of patients who were taking
concomitant MTX or systemic corticosteroid therapy was
decreased from 73.7 to 47.4% and from 22 to 4.7%,
respectively, compared to treatment baseline. Only a small
proportion of patients had evidence or articular or extra-
articular damage.
These figures do not apply to the systemic arthritis
subgroup, however, as there was a relatively greater pro-
portion of patients with this JIA category among those
who were discontinued or lost to follow-up than among
those who were still taking ETN. A number of prior
studies have shown that anti-TNF agents are less effect-
ive in the systemic subset of JIA [2, 3, 5, 12, 25–27]. This
phenomenon has been attributed to interleukin (IL)-1
and IL-6 playing a greater pathogenetic role than TNF
in systemic arthritis [28, 29]. However, a sizeable propor-
tion of our patients with systemic arthritis had ID or
LDA at cross-sectional visit or had ETN discontinued
for the achievement of disease remission. Some studies
have suggested that TNF inhibitors may be effective in
the later afebrile disease phase of systemic JIA, charac-
terized by chronic arthritis [4, 30].
The results of parent-centered assessments at cross-
sectional visit corroborated the good disease status
achieved by patients on continued ETN therapy, as
52.4% of them had normal physical function, a few had
impairment in HRQL, 51.2% had no pain, 76% had no
morning stiffness, and 67.9% were judged as having dis-
ease remission by the parent. In addition, 82.7% of par-
ents were satisfied with their child’s illness outcome.
That around half of the patients had persistent pain is
worrying, however, although only 7.6% had severe pain
(i.e.,a pain level > 5 on a 0-10 VAS). A recent study
found that a subgroup of JIA patients treated with TNF
inhibitors had continuous pain despite good disease con-
trol [31]. These observations underscore the possible
persistence of clinically significant pain in children
treated with biologic agents, even when good disease
control is achieved. Constant monitoring of pain and its
determinants remains, therefore, a clinical priority in the
current biologic era [32]. Notably, use of nonsteroidal
anti-inflammatory drugs before ETN start was reported
for only 58% of patients. This finding underscores the
recent change in treatment practice related to these
medications.
ETN was generally well tolerated, as clinically signifi-
cant adverse events were reported for 27.8% of patients
and the medication was discontinued for side effects in
99 patients (9.5%). Overall, safety findings are consistent
with those reported in other analyses of ETN in JIA
[2, 4, 26, 33, 34].
New-onset or recurrent uveitis was the adverse event
most commonly recorded in the entire study sample and
was most frequently responsible for treatment discon-
tinuation. This finding is important as ocular inflamma-
tion has been postulated to be related to ETN [35, 36].
It should be taken into account, however, that our sam-
ple included a high proportion of children with early-
onset and ANA-positive disease, who have a high back-
ground risk of uveitis [37]. It has been hypothesized that
ETN may not directly cause the development of uveitis,
but the discontinuation of MTX upon successful arth-
ritis control may pose the patient at risk [38]. Recent
data have shown that MTX may prevent the onset of
uveitis in children with JIA [39, 40]. Nevertheless, many
patients who had ETN discontinued for uveitis were
likely switched to adalimumab and infliximab, which are
nowadays recommended as second-line therapeutic op-
tion among patients with JIA and uveitis [41]. Notably,
the frequency of uveitis was higher among patients
treated in the earlier years of ETN use than in those
who received ETN in the recent years (16.6% versus
7.5%), which suggests that the increased awareness of
the possible relation of ETN with ocular inflammation
might have led to decrease its prevalence. In addition,
the 38 patients who had ETN discontinued because of
the occurrence of uveitis had an average treatment
duration longer than that of the entire patient cohort.
Previous studies have shown that the risk of infection
is increased in children with JIA receiving ETN as com-
pared to those treated with MTX [4, 26, 30, 42, 43]. In-
fection was the second most prevalent adverse event in
our cohort, but only ranked fourth among the causes of
treatment discontinuation for side effects. Indeed, infec-
tious complications were most frequently mild as in only
13 of 68 cases they led to treatment withdrawal. It is
noteworthy that only 1 patient had tuberculosis. One
patient, who was taking ETN and MTX, died for a
fulminant streptococcal sepsis. A similar case has been
reported previously [44].
Neuropsychiatric symptoms were the second most fre-
quent cause of treatment discontinuation for adverse
events. A high frequency of psychiatric symptoms was
reported in other studies of ETN in JIA [2, 4]. It is, how-
ever, difficult to dissect the responsibility of the
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medication itself from behavioral or mood disorders re-
lated to psychological disease burden or due to other
medications, namely MTX [45]. Unfortunately, the design
of our study did not allow us to establish whether they
were related to ETN by investigating whether they had
disappeared after its withdrawal.
Ten patients developed an inflammatory bowel disease
(IBD). Although this phenomenon has been observed in
other studies [46, 47], the relationship between ETN and
gut inflammation is unclear. It has been speculated that
an already established subclinical IBD may be activated
by the use of TNF inhibitors [48]. Along this line, it is
conceivable that children with enthesitis related arthritis
are more susceptible to this phenomenon, as IBD are
closely associated with spondyloarthropathies [49]. How-
ever, only 2 of the 10 patients who developed IBD in our
cohort had this JIA category. The role of ETN in indu-
cing IBD deserves further investigations.
In spite of earlier alarming data [50], there is currently
no evidence of an increased incidence of malignancy
among patients exposed to TNF inhibitors compared
with MTX [36], and the increased risk of malignancy
has been attributed to the autoimmune disease itself, ra-
ther than to treatment with TNF inhibitors [51–53].
Two malignancies were observed in our cohort, one thy-
roid carcinoma and one bladder carcinoma. This fre-
quency is in the range of that observed in other studies
of similar size [38, 54]. These reports underscore the
need to follow carefully JIA patients exposed to biologics
and to continue long-term observation in adulthood.
Further knowledge about risk profiles of these medica-
tions will be gained with for the accumulation of long-
term data through national and international registries
[55]. In 2011, the Pediatric Rheumatology INternational
Trials Organisation (PRINTO) and the Pediatric Rheuma-
tology European Society (PRES) created an international
observational registry aimed to enroll children with JIA
treated with methotrexate or biologic medications in any
available formulations. This registry is named “Pharma-
covigilance in JIA patients treated with biologic agents
and/or MTX - Pharmachild” (European Union grant
260353) and is primarily aimed to evaluate the long-term
safety of these therapeutic agents [56].
The findings of our study should be interpreted in the
light of some potential caveats. Because our analysis was
nonrandomized and observational, we cannot exclude
that children still on treatment with ETN at the time of
the study had a less severe disease than those discontinued
from the medication or lost to follow-up. However,
although the method used to assess the treatment out-
come was different, the percentage of patients who were
in clinical remission was similar between cross-sectional
and retrospective populations. The disease status was only
assessed at a single point of time, which precluded the
possibility to establish whether clinical remission was sus-
tained while receiving treatment or after its interruption,
and how many patients were retreated. Adverse events
were recorded through the retrospective review of
patients’ clinical charts. A retrospective analysis is subject
to missing and possibly erroneous data. Thus, some side
effects may be underreported. Notably, owing to the non-
prospective nature of data collection, we could not calcu-
late the crude rates of adverse events per 100 person-years
of exposure. Furthermore, we acknowledge that attribu-
tion of adverse events was not done. The main strengths
of our study are related to the size of the cohort, the
methodology used for case ascertainment which mini-
mized potential selection bias, and the detailed procedures
used to assess patients on ongoing ETN therapy.
Conclusions
Our study shows that around half of children with non-
systemic JIA achieve complete disease quiescence under
treatment with ETN. The medication was overall well
tolerated, as only one quarter of patients experienced
clinically significant adverse events and less than 10%
had treatment discontinued for toxicity.
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